CI capabilities

1. © 2015 Indegene. All rights reserved.
Competitive Intelligence
and Analytics

2. 2
Next-generation solutions enabling global healthcare
organizations to improve health and business outcomes.
About Indegene
LIFESCIENCES PAYERS PROVIDERS

3. 3
Customers

4. 4
Solutions for the Healthcare Stakeholders
Comprehensive solutions for Life Sciences , Payers & Providers to improve health outcomes,
increase revenue, optimize costs, and engage customers better.
Risk and Quality
Solutions
Clinical
Effectiveness
Quality Improvement -
STARS / QRS / HEDIS
| Risk Adjustment
| Operations – MRR ,
Coding , Analytics
Provider and Member
Engagement | Clinical &
Financial Analytics | Care
management
Medical
Solutions
Marketing
Solutions
Labelling
| Regulatory and Safety
Writing | Promotional
Review | HEOR
MCM | Digital factory
| Commercial
Analytics
| Learning &
Development
Population Health
Management
Population Analytics |
Care Management |
Patient and Physician
engagement
| Pharmacy Support
LIFESCIENCES PAYERS PROVIDERS

5. 5
The ATOM Advantage
Proprietary Medical interactions
analytic frameworks to drive
insights for commercialization
and better health outcomes
Suite of platforms to
drive effective medical
interactions
Robust , scalable & secure
global operational expertise
Deep Expertise in medical science
and network of clinicians across
therapies and countries

6. 6
Next-generation Healthcare Platforms

7. 7
Deep & Diverse Talent
72%
INDIA
5%
CANADA
9%
CHINA
14%
US & EU
43%
OPERATIONS
15%
ANALYTICS
18%
TECHNOLOGY
24%
MEDICAL EXPERTISE
55%
MALE
45%
FEMALE

8. 8
Best in Class Operations
Local Client
Support
• Local client servicing
support
• In 50 countries across
US, Europe and Asia
• Regulatory and local
market understanding
Delivery and Data
Centers
• 4 global delivery
centers across US,
India and China
• Data centers across
US , Latin America ,
India and China
Innovation
Hubs
• Digital and mobility
centres in LA &
Montreal, Canada
Quality
Management
ISO 9001, 27001

9. 9
Analyst and Industry Acclaim
Life Sciences, Sales and
Marketing, Strategic Consulting
Life Sciences, Sales
and Marketing BPO
IDC MARKETSCAPE
Capabilities
Capabilities
Strategies Strategies

10. 10
Research, Analytics and Insights Services
 Market Sizing
 New Market Estimation
 Sensitivity Studies
 Emerging Market Models
 Pricing Research
 Competitor Activity Tracking
 Disease Landscaping
 Pipeline and Portfolio Analysis
 Scenario Planning
 Market Research
 Sales Force Effectiveness
 Market Data Analytics
 Performance Dashboards
 Epidemiology Studies
 Regulatory Support Services
 Patient Journey Assessment
 Analysis of Health Systems
 Pricing Research
 Payer Research
Domain-intensive integrated insights across the pharma value chain
R&D and Regulatory Affairs
Business Development and
Licensing
Medical Affairs Commercial and Marketing
Sales and Client
Engagement
 Clinical Trial Analysis
 Trial Timeline Analysis and Forecasting
 Clinical Operations Support
 IP and Patent Analysis
 Publication Analysis
 Channel Mix Optimisation
 Social Media Monitoring and Analytics
 ROI Analysis
 Multichannel Segmentation and Targeting
CONFIDENTIAL & PROPRIETARY

11. Competitive Environmental Monitoring
11Confidential
• Track evolution of environmental trends, sequence of events or streams of activities
• Alert the firm to critical trends before competitors recognize them
• Enable faster and timely decision making
Daily Weekly Monthly
Quarterly
Reports
Analysis/
Key insights
Analysis/
Key insights
Analysis/
Key insights
Indegene
News
Monitoring
Services
Commercial News
Regulatory Update
Clinical Trial Updates
Therapy Area
Conference News
General News
CI Areas
Custom Alerts
Newsletters
Web-based Platform
Mode of Delivery
Reports

12. Methodology Overview
12Confidential
Reviewing collected information
SourcesCollation
Human
Intelligence
Checking for reliability of sources for each selected item
Selecting relevant information
Summarising the information and providing insights
Checking for redundancy
Deliverable
Repository
Daily/Weekly/Monthly/Quarterly
Newsletters/Reports – An initial baseline report
and subsequent update reports
Client-subscribed/
shared data if any
Conferences Syndicated Databases News Social Media Blogs Publications

13. www.indegene.com
13
CONFIDENTIAL & PROPRIETARY
Methodology - Execution Process
1
Indegene’s team of
subject matter experts
will review the
information and asses
the relevance and
importance of the same
2
Based on their domain
expertise, they will
comprehend the
information and build a
story around the
findings of the news
3
Next, they will link the
context of the same
with pre-existing
understanding in order
to bring out the specific
implication of the
finding
Human Intelligence – Selection, assessment and critical analysis
• Indegene experts will create a write up of their viewpoints on
noteworthy stories on a daily or weekly basis. This will contain a
more detailed analysis of the information.
Viewpoints
• Additionally, Indegene will select certain significant advances or
trends (for e.g. practice changing updates from a conference) and
create a in- depth feature from the same
Monthly features

14. News Coverage: Key Sources*
14Confidential
• Bioportfolio.com
• Bioworld
• Bloomberg.com
• Business week
• CNBC
• Diabetes.org
• DowJones.com
• Endocrine
• FDA.Gov
• Fiercebiotech.com
• First Word Plus
• Forbes
• Market Watch
• Medical News Today
• Medpage Today
• Medscape
• NEJM
• Newsrx.com
• Pharmalive
• Pharmalot.com
• PR News Letter
• Reuters Health Care
• The Lancet
• Washington Post
• Competitor Company Websites
• Other subscribed databases of the clients
Therapy Area News
• Clinical trials.gov
• DYONISUS: Indegene propriety database, an
automated data monitor that collects and
categories news from 400+ preselected
sources in real-time setting
• Analyst reports
• WHO clinical trial registry
• Company & country-specific clinical trial
registries
Clinical Trial News
• Competitor companies’ Web sites
• Company news releases
• Company annual and quarterly filings and
reports
• Company presentations and press releases
• Key congresses during the period
Competitor News
• Country-specific pharmaceutical, regulatory,
registry sites, articles, etc
Client Provided Pipeline database such as:
• Thomson Pharma
• Adis Insights
• IDDB3
• Factiva
• Datamonitor Reports
• Analyst Reports
Other Sources
* Only indicative, not exhaustive

15. Multiple Delivery Formats
15Confidential
SharePoint Web Portal
Excel

16. Case Studies
16Confidential

17. Objective: To develop an online tracking tool that will serve as a one stop shop for information on key developments in the entire biosimilar
space and monitor activity of key biosimilar players on a regular basis.
Client Speak
“Appreciate all your hard work and diligent support all year round.”
Solution: A web-based competitive intelligence portal inclusive of:
Real-time updates of technical, commercial, and regulatory biosimilar developments globally.
Activity monitor of key biosimilar players (watch list) across North America, Europe, Asia, and Latin America.
Emerging player tracker, Publication tracker
Reporting tool for innovator firms’ defense strategy.
Key news tracker.
Case Study: Biosimilar Competitive Intelligence Platform
Portal Features
Competitor Profile
Information retrieval
between particular
dates
In-built PDF converter
Product launch timeline
Competitive activity
report
Product portfolio
Relevant news
Key personnel
Corporate publications
Company statements
Expertise
Demonstrated
Multi-sourced real-time domain monitoring
Emerging market tracking
Conference presentation tracking
Company-, geography-, and molecule- based
intelligence generation
Key event monitoring (conferences)
KEY FACT 1:
The project has
been operational
for 3 years.
KEY FACT 2:
Over 200 log-in IDs
issued.

18. www.indegene.com
18
CONFIDENTIAL & PROPRIETARY
Snapshot of Biosimilar Platform Competitive Intelligence
Platform
Enter search term
General News
Development & Regulatory Activities
Commercialization & Lobbying
Intas to focus on developing biosimilars for US, EU Date:
Jan 14, 2010
Biocon signs MOU with BiotechCorp to explore
collaboration Date: Jan 14, 2010
Teva among final three bidders for ratiopharm Date: Jan
19, 2010
Operations & Manufacturing
HHS Budget plan may enable FDA to provide regulatory
pathways for biosimilars Date: Jan 17, 2010
EGA outlines “Vision 2015” plan for generics and
biosimilars in Europe Date: Jan 14, 2010
Generics would offer USD 5 billion for shorter exclusivity
period Date: Jan 11, 2010
Shortcuts
Last 7 days
Last 15 days
This month
Last month
Top Companies
Top Sections
Monoclonal
Antibodies
GCSF
EPO
Add Users Contact Us Change Password LogoutHome
General NewsDevelopment & Regulatory Activities Commercialization & Lobbying Operations & Manufacturing
Biosimilar
Dashboard
News
Competitive Activity
Monitor
Competitor
Tracker
Global Biosimilar
Portfolio SEARCH
Company 1
Company 2
Company 3
Biosimilar
Events
FDA to review Teva biosimilar of Amgen's Neupogen Date:
Feb 2, 2010
3SBio Inc. Applies for SFDA Registrational Trial for
Feraheme Date: Jan 08, 2010
Study: HX575 is therapeutically equivalent to comparator
epoetin alpha Date: Nov 01, 2010
DRL invests in biosimilar facility Date: Jan 20, 2010
Dong-A plans to build new plant to raise output Date: Jan
14, 2010
3SBio's new manufacturing facility in Shenyang to produce
EPIAO and TPIAO Date: Nov 13, 2009

19. 19
P
Brand Planning:
Strategic projects with broad business objectives, involving multiple stakeholders
To help the client in developing a brand plan for their asset by developing a detailed assessment of TA and competitive landscape supplemented by additional analysis including customer
behaviors, buying process, market access and pricing
Objective
Crisp breakdown of tumor types showing a
comparative assessment and risk-factors at the
beginning of the slide
Patient pool break-down as per lines of
treatment across geography
CONFIDENTIAL & PROPRIETARY
Sample

20. 20
P
Brand Planning: Snapshots
• Trial maps with trial protocol details
• Can be provided in spreadsheets also
• Value added analysis includes
probability of regulatory success and
end-date estimation
• Assessments based on possible
prospective scenarios
• Typically followed up with a quantitative
market sizing of each scenarios
CONFIDENTIAL & PROPRIETARY
Sample

21. 21
P
Commercial Assessments and Market Sizing
Triangulating quantitative data from multiple sources to arrive at commercial assessments and Insights
To assess the future commercial opportunities/attractiveness of the lymphoma market. The major focus is on Non-Hodgkin Lymphoma subtypes such as follicular lymphoma (FL), diffuse
large B-cell lymphoma (DLBCL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). The broader business question was to determine whether to pursue further research
in this area and to justify the same.
Evolving Epidemiology in each country followed by
split based on treatable and treated patient pool
CONFIDENTIAL & PROPRIETARY
Objective Sample

22. 22
P
Commercial Assessments and Market Sizing: Snapshots
Across line split of sales by drug class-
current as well as future
Across country prospective market size
and leading drugs
CONFIDENTIAL & PROPRIETARY
Sample

23. 23
P
Clinical Trials, Pipeline Assessments
• Multi-parameter and protocol assessments of clinical studies
• Presentations as trial maps, graphic details or dynamic spreadsheets.
• Online tools for clinical trial analytics and trial modeler
• Supplementing probability of success, unmet need assessments and scenario planning
“This map is very impressive! I especially like how easy it is to use (user friendly), and how
the updated version includes the additional compounds and press releases. Very nice job.”
CONFIDENTIAL & PROPRIETARY

24. 24
P
Exploratory assessments- Oncolytics
Assessment of niche areas to determine opportunities and lucrativeness
Exploratory assessment of Oncolytics as a potential/novel approach to cancer therapeutics. The types of oncolytics platform and any successes of clinical PoC.
The assessment gauged the current landscape of Oncolytics- their usage in multiple tumor types and eventually their lucrativeness as a potential in-licensing candidates
Objective
CONFIDENTIAL & PROPRIETARY
Sample

25. 25
P
In-licensing Dashboards
To develop a dashboard which will help identify and prioritize the pipeline oncolytic platform candidates and also help rank them based on weightages given to
various parameters to aid in the candidate selection for acquisition/in-licensing
Objective
Methodology and assumptions
developed by Indegene Excel dashboard on oncolytics
candidate ranked based on
lucurativeness for in-licensing
CONFIDENTIAL & PROPRIETARY
Sample

26. 26
P
Epidemiology, Patient Flow
• Team of Epidemiologist well versed with various aspects of epidemiology assessments
• Detailed Epidemiology segregated across lines of therapies, severity, geography and stages of patient journey
• Qualitative and Quantitative patient flow; expertise in multiple TAs.
• Supplementing Market sizing, forecasting, HEOR assignments
“In general, I am very happy with the ….. Report”
“Thanks a lot for this team ! Looks much better”
CONFIDENTIAL & PROPRIETARY

27. 27
P
Web Platform Output Snapshot (1/2)
Platform homepage
Latest
updated
news
Scientific monitor:
Clinical trials, journals, and
conferences
Market monitor:
monthly update report
for approved products,
pipeline products,
targets, and company
Therapy landscape:
• Statistics: updated quarterly or
based on availability of information
• Staging: dynamically linked to
other sections
• Guidelines: updated quarterly
Key opinion leader database:
• Individuals: updated monthly
• Cancer groups: updated monthly
Easy shortcuts to
search for news
Patient opinion report
• News updated on a daily basis
• Shortcuts and ready reference for
therapy/product updates
CONFIDENTIAL & PROPRIETARY
Sample

28. 28
P
Web Platform Output Snapshot (2/2)
Weekly alert
Click here to go to
detailed news
Click here to go directly to
Web site link
Indicates level of
relevance to client’s
requirements
CONFIDENTIAL & PROPRIETARY
Sample

29. 29
P
Conference Coverage
• Live, virtual and offsite conference coverage service
• Service includes- Pre-conference abstracts hand-book preparation and prioritization, live conference attending, daily debriefing, OL
engagement, post-conference report and summaries
• Covered major conferences in Oncology and Cardiology space- US and EU
“I am very happy with the excellent ASH update you delivered within the discussed
timeline. Thanks for a job well done.”
CONFIDENTIAL & PROPRIETARY

30. 30
KOL Research- Identification, Profiling and Mapping
P
To identify and profile the opinion leaders in a therapy area. The detailed profile covered their involvement in clinical trials, presentations of studies, affiliation to
a corporate unit and publications along with their contact details. As a next step, Indegene also ranked by assigning certain pre-agreed weightings and scores to
each of their activity.
Objective Sample
CONFIDENTIAL & PROPRIETARY

31. 31
P
Analytics: Dash-boarding
Patient Based & Performance Dashboards Delivered on a Regular Basis
To develop insightful, crisp, and non-CI centric dashboard, based on Ipsos synovate data in a pre-specified template. Such dashboards are being developed for as much as 8 tumor
types and updated and delivered every quarter since 2013
CONFIDENTIAL & PROPRIETARY
Objective Sample

32. 32
P
Dashboard Reports with Insights
Indegene provides option for reports and insights on various user interfaces
Reports and Insights
MS Excel/VBA based
dashboards
iPhone enabled
dashboards
iPad enabled dashboardsShare Point enabled Dashboards Web based dashboards
CONFIDENTIAL & PROPRIETARY

33. 33
Thank You
CONFIDENTIAL & PROPRIETARY
Thank You!